Veranova Expands ADC and HPAPI Capabilities in the US

Veranova, a US contract development and manufacturing organization (CDMO), has begun expanding its antibody-drug conjugate (ADC) and high-potency active pharmaceutical ingredients (HPAPI) development and manufacturing capabilities at its US facility in Devens, Massachusetts.

The company said the expected $30 million investment will build on the site’s existing development and manufacturing capabilities and will meet growing demand in the US for robust production capacity for ADCs and other potent small molecules.

The expansion will include a new high-efficiency process development laboratory and two new cGMP suites designed to handle high-potency compounds with occupational exposure limits (OELs) below 0.01 µg/m³. The new facility will be equipped to handle high-potency compounds, ADC linker-payloads and other complex molecules.

"At Veranova, we recognize the growing need for the development and manufacturing of ADCs and other highly potent compounds," said Mike Riley, Veranova CEO. "This investment demonstrates our commitment to providing state-of-the-art capacity and capabilities to enable these next-generation therapies to reach patients, and is an important milestone in our efforts to advance Veranova's broader growth strategy."

Located in Devens, near Boston's pharmaceutical and biotech hub, Veranova's facility is an FDA-approved facility that enables development, clinical manufacturing, and commercial production under one roof.